AstraZeneca Acquires Icosavax

Eli Lilly to Acquire Vaccine Company for Up to $1.55 Billion

May 27, 2026

Biotechnology

Vaccine Company, Inc. announced it has entered into a definitive agreement to be acquired by Eli Lilly and Company in a deal valued at up to $1.55 billion, including upfront and milestone-based payments. The acquisition is intended to accelerate development of Vaccine Company’s next-generation in vivo nanoparticle (IVN) vaccine platform, led by a Phase 1-ready Epstein-Barr virus (EBV) vaccine candidate targeting infectious mononucleosis and longer-term EBV-linked diseases.

Sanofi to Acquire Vicebio for Up to $1.6 Billion

July 25, 2025

Healthcare Services

Sanofi has entered an exclusive, definitive agreement to acquire biopharmaceutical company Vicebio for up to US$1.6 billion, comprising a US$1.15 billion upfront payment plus up to US$450 million in development and regulatory milestones. The deal is aimed at accelerating Vicebio’s next-generation respiratory virus vaccine platform, including lead candidate VXB-241 targeting RSV and hMPV.

AstraZeneca to Acquire EsoBiotec

March 18, 2025

Biotechnology

AstraZeneca has entered into a definitive agreement to acquire EsoBiotec, a biotechnology company developing in vivo cell therapies. The deal is valued at up to $1 billion on a cash and debt-free basis, with an initial $425 million payment upon closing plus up to $575 million in contingent milestone consideration. The transaction is expected to close in Q2 2025, subject to regulatory approvals.

Vertex Pharmaceuticals to Acquire Alpine Immune Sciences

April 10, 2024

Biotechnology

Vertex Pharmaceuticals entered into a definitive agreement to acquire Alpine Immune Sciences for $65 per share in cash, valuing the deal at approximately $4.9 billion. The transaction is unanimously approved by both boards and is anticipated to close later in the second quarter of 2024.

AstraZeneca Acquires Fusion Pharmaceuticals

March 19, 2024

Biotechnology

AstraZeneca has entered into a definitive agreement to acquire Fusion Pharmaceuticals Inc., a clinical-stage company developing next-generation actinium-based radioconjugates, for $21.00 per share in cash plus a non-transferable contingent value right that could bring the total to approximately $2.4 billion. The acquisition adds Fusion's pipeline (including FPI-2265 for mCRPC), R&D and manufacturing capabilities in radioconjugates and strengthens AstraZeneca's oncology portfolio and presence in Canada.

GSK Acquires Affinivax, Inc.

August 16, 2022

Biotechnology

GSK plc acquired clinical-stage biopharmaceutical company Affinivax, Inc., paying $2.1 billion upfront and up to $1.2 billion in potential development milestones to gain the MAPS vaccine platform and a 24‑valent pneumococcal vaccine candidate (AFX3772) in development. The acquisition (100% of outstanding shares) expands GSK's vaccines R&D capabilities and pipeline, with AFX3772 in phase II and preparations underway for phase III.